Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

Light holder MV Capital acquires 5,000 debenture units

Pre-revenue AI diagnostics company closes dilutive financing to fund regulatory milestones amid going concern risks.

By The Northwire Desk — AI Analysis Jun 22, 2026 · 18:41 ALGO · 0.265 Light AI Inc
Executive Summary
  • Light AI Inc. closed a private placement of secured convertible debenture units with MV Capital LP for gross proceeds of C$5,000,000.
  • Each unit comprises a $1,000, 12% secured convertible debenture maturing in 24 months and 8,000 common share purchase warrants exercisable at $0.25 per share for 36 months.
  • Debentures are convertible at $0.125 per share. Interest accrues quarterly and is payable on the earlier of maturity, prepayment, or conversion.
  • Proceeds are allocated to general working capital, completion of an ISO 13485/QMS audit, and submission for Health Canada registration.
  • MV Capital LP received an investor rights agreement granting board nomination rights and pro rata participation in future financings.
  • An ownership cap restricts MV Capital from converting or exercising if it would exceed 19.9% of outstanding shares without shareholder and exchange approvals.
  • A statutory hold period of four months and one day applies to all securities.
Material Impact
  • The closing of this financing extends the company's cash runway but introduces significant dilution and expensive debt-like terms.
  • Potential dilution is substantial: 40 million conversion shares plus 40 million warrant shares could be issued, representing roughly 65% dilution on the current ~122 million share count, though capped at 19.9% without regulatory approval.
  • The 12% interest rate and low exercise/conversion prices ($0.25 and $0.125 respectively) reflect a high cost of capital, typical for pre-revenue, high-risk companies with limited bargaining power.
  • The capital is strictly earmarked for near-term regulatory and compliance milestones (ISO audit, Health Canada submission), which are necessary to progress toward the stated mid-2026 commercialization target.
  • The financing does not materially change the company's pre-revenue status or its reliance on future capital raises to survive.
ALGO · Price
Company Overview
  • Light AI Inc. is a pre-revenue artificial intelligence diagnostics company developing a smartphone-based Software as a Medical Device (SaMD).
  • Its flagship product, QuickScan™ Strep A, uses AI algorithms to analyze smartphone images of throats to detect Group A Streptococcus (GAS) infections, eliminating the need for swabs or lab tests.
  • The platform targets community, school, and urgent-care settings, aiming to reduce unnecessary physician visits and curb antibiotic overuse.
  • Pre-FDA validation metrics claim 96.57% accuracy and a 100% Negative Predictive Value for distinguishing viral vs. bacterial pharyngitis.
  • The company is transitioning from product development to commercialization, with a dual-track strategy focusing on US FDA and Health Canada regulatory approvals.
Read the original news release →

More from Light AI Inc

Jun 29, 2026 · 07:00

Pre-revenue AI diagnostics developer advances regulatory clearance for smartphone-based Strep A detection amid persistent cash burn and dilution risk.

Production / Operations Jun 19, 2026 · 18:00

Light AI Announces Closing of C$5,000,000 Secured Convertible Debenture Unit Financing

Financings Jun 15, 2026 · 18:25

Light AI pilots Strep A diagnostic in NZ as FDA pivotal trial launches, but pre-revenue status and going concern risk persist.

Production / Operations Jun 04, 2026 · 07:00

Light AI Advances FDA Pivotal Trial for Strep A AI Diagnostic Amid Cash Burn and Dilutive Financing

Regulatory May 21, 2026 · 07:15

Light AI’s C$5 Million Lifeline Comes With Dilutive Terms and Board Strings as Cash Burn Intensifies

Financings May 15, 2026 · 18:58

Pre-revenue diagnostics firm narrows losses but liquidity runway tightens ahead of commercial launch

Earnings